The neighborhood pharmacy has always been a place of trust, a familiar corner where you pick up your blood pressure meds or get a quick flu shot. However, the landscape is shifting in a big way. Thanks to the 2024 FDA final guidance on decentralized elements, your local independent pharmacist is no longer just a…
Meet Ari Cofini at DPHARM 2026 If you are attending DPHARM 2026 in Boston, September 15-16, Reach out to Ari Cofini from our team who will be there, and learn about our innovative solutions for clinical trial recruitment, site engagement, and patient-centric research. See you there!
The Pharmacy as a Clinical Research Hub: Navigating Investigative Roles under the 2024 FDA Guidance The landscape of clinical research is currently undergoing its most significant structural transformation since the formalization of Good Clinical Practice (GCP) standards. On September 17, 2024, the U.S. Food and Drug Administration (FDA) released its final guidance, “Conducting Clinical Trials…
Written by: Andy Russell, Vice President, Growth & Product Strategy at RxE2The San Diego Signal: An Industry Carrying a Heavy Load There was a moment coming out of GCSG this year where something started to feel different. Not because we suddenly discovered new problems. We didn’t. If anything, the industry showed just how well it…
Introduction Community pharmacies have long been the most accessible point of care for patients, and their role in clinical research is becoming increasingly vital. Pharmacists are bridging the gap between innovative medical studies and the patients who need them most. We sat down with Dr. Tammy Bullock , a clinical pharmacist at Osterhaus Pharmacy, to discuss…
The recent 2026 U.S. Annual Conference of the Global Clinical Supplies Group in San Diego felt different than previous years. In the past, these gatherings often focused on the promise of distant technologies or abstract innovations. However, the tone this year was grounded in a heavy sense of pragmatism. Leaders from the largest pharmaceutical organizations…
On April 21st, 2026, RxE2 hosted a landmark virtual fireside chat between CEO Gerald Finken and Craig Lipset, Co-Founder of the Decentralized Trials & Research Alliance (DTRA). The conversation moved beyond the buzzwords of virtual trials to address the fundamental architecture of how we develop medicines. The Crisis of Access: Three Inputs, One Major Bottleneck…
The clinical trial landscape is changing. Are you ready for what’s next? Decentralized Clinical Trials (DCTs) have evolved rapidly since their initial inception over a decade ago. While the COVID-19 pandemic accelerated their adoption, the industry is now at a crossroads. As we move beyond the initial hype, the focus has shifted toward sustainability, cost-effectiveness,…
Revolutionizing Clinical Research Through the Power of Community RxE2 is thrilled to be exhibiting at the GCSG 2026 US Conference in San Diego from April 26–29! Traditional clinical research often faces the “80/20 Problem”: while 80% of healthcare treatment occurs in the community, roughly 80% of research is clustered at major academic medical centers. This…
Introduction Following our deep dive into the mechanics of clinical trials with Austin Tull, we continue our series aimed at demystifying the evolving landscape of clinical research. While the “what” of clinical trials is rooted in safety and efficacy, the “how” is undergoing a radical transformation. This shift is known as Decentralized Clinical Trials (DCT),…